These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 20813363)

  • 1. Microdose gonadotropin-releasing hormone agonist in the absence of exogenous gonadotropins is not sufficient to induce multiple follicle development.
    Chung K; Fogle R; Bendikson K; Christenson K; Paulson R
    Fertil Steril; 2011 Jan; 95(1):317-9. PubMed ID: 20813363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteal phase estradiol versus luteal phase estradiol and antagonist protocol for controlled ovarian stimulation before in vitro fertilization in poor responders.
    Elassar A; Mann JS; Engmann L; Nulsen J; Benadiva C
    Fertil Steril; 2011 Jan; 95(1):324-6. PubMed ID: 20797708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle.
    Kahraman K; Berker B; Atabekoglu CS; Sonmezer M; Cetinkaya E; Aytac R; Satiroglu H
    Fertil Steril; 2009 Jun; 91(6):2437-44. PubMed ID: 18555238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose gonadotropin-releasing hormone agonist protocol for patients with a history of poor in vitro fertilization outcomes.
    Weitzman VN; Engmann L; DiLuigi A; Maier D; Nulsen J; Benadiva C
    Fertil Steril; 2009 Jul; 92(1):226-30. PubMed ID: 18675961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of gonadotropin-releasing hormone analog and human menopausal gonadotropins for ovulation induction in premature ovarian failure.
    Letterie G; Miyazawa K
    Acta Obstet Gynecol Scand; 1989; 68(6):571-3. PubMed ID: 2520819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early and late hormonal responses to the microdose gonadotropin-releasing hormone agonist in normal menstruating women.
    Park WI; Kim SS; Chung HR; Shin SY; Lee JY
    Fertil Steril; 2004 Apr; 81(4):1067-72. PubMed ID: 15066465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRH antagonist/letrozole versus microdose GnRH agonist flare protocol in poor responders undergoing in vitro fertilization.
    Davar R; Oskouian H; Ahmadi S; Firouzabadi RD
    Taiwan J Obstet Gynecol; 2010 Sep; 49(3):297-301. PubMed ID: 21056314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol?
    Schoolcraft WB; Surrey ES; Minjarez DA; Stevens JM; Gardner DK
    Fertil Steril; 2008 Jan; 89(1):151-6. PubMed ID: 17482177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New trends in combined use of gonadotropin-releasing hormone antagonists with gonadotropins or pulsatile gonadotropin-releasing hormone in ovulation induction and assisted reproductive technologies.
    Gordon K; Danforth DR; Williams RF; Hodgen GD
    Curr Opin Obstet Gynecol; 1992 Oct; 4(5):690-6. PubMed ID: 1391640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hormone profile and follicle development in ovarian stimulation treatment for in vitro fertilization. II. Prolactin, estradiol and progesterone profile].
    Sudik R; Fliess FR; Kunkel S
    Zentralbl Gynakol; 1989; 111(9):567-80. PubMed ID: 2500795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial.
    Fatemi HM; Oberyé J; Popovic-Todorovic B; Witjes H; Mannaerts B; Devroey P
    Fertil Steril; 2010 Oct; 94(5):1922-4. PubMed ID: 20149360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
    Doldi N; Persico P; Di Sebastiano F; Marsiglio E; Ferrari A
    Gynecol Endocrinol; 2006 May; 22(5):235-8. PubMed ID: 16785142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response.
    De Placido G; Mollo A; Clarizia R; Strina I; Conforti S; Alviggi C
    Fertil Steril; 2006 Jan; 85(1):247-50. PubMed ID: 16412769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovulation induction with pulsatile gonadotropin-releasing hormone (GnRH) or gonadotropins in a case of hypothalamic amenorrhea and diabetes insipidus.
    Georgopoulos NA; Markou KB; Pappas AP; Protonatariou A; Vagenakis GA; Sykiotis GP; Dimopoulos PA; Tzingounis VA
    Gynecol Endocrinol; 2001 Dec; 15(6):421-5. PubMed ID: 11826765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poor responder protocols for in-vitro fertilization: options and results.
    Loutradis D; Vomvolaki E; Drakakis P
    Curr Opin Obstet Gynecol; 2008 Aug; 20(4):374-8. PubMed ID: 18660689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development.
    Lainas TG; Petsas GK; Zorzovilis IZ; Iliadis GS; Lainas GT; Cazlaris HE; Kolibianakis EM
    Hum Reprod; 2007 Jun; 22(6):1540-6. PubMed ID: 17347165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.